Omega-DEK
Phase 2Small molecule
Omega-DEK is one of 3 small molecule programs targeting Childhood Apraxia of Speech. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
2 competitors in Childhood Apraxia of Speech
#DrugCompanyPhaseTrials
1Methylphenidate Hydrochloride
TakedaPhase 2
L-Carnitine
IIperboreal Pharma Srl
Phase 2
Omega-DEK
CClaudia R. Morris
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Childhood Apraxia of Speech1 trial
Role of Omega-DEK in Childhood Apraxia of Speech
Not yet recruiting·—·Phase 2·NCT07216001·34 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Omega-DEK. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CClaudia R. Morris